Sensei Biotherapeutics Presents New Preclinical Data on SNS-103 Targeting ENTPDase1 (CD39) at the American Association for Cancer Research (AACR) Annual Meeting 2023
18 Aprile 2023 - 10:05PM
Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology
company focused on the discovery and development of next-generation
therapeutics for cancer patients, today presented new preclinical
data on its SNS-103 program aimed at developing a conditionally
active, monoclonal antibody program targeting ENTPDase1 (also known
as CD39) at the American Association for Cancer Research (AACR)
Annual Meeting 2023.
“CD39 is an important target because it is the rate-limiting
enzyme that creates an immunosuppressive tumor microenvironment
through the production of adenosine. However, it has been difficult
to target effectively due to its broad expression on various cells
in both tumors and normal tissues,” said Edward van der Horst,
Ph.D., Chief Scientific Officer at Sensei Biotherapeutics. “The
hypothesis driving our program is that a pH-sensitive antibody may
inhibit the pro-tumoral activities of CD39 selectively within the
tumor microenvironment while avoiding on-target/off-tumor binding
and pharmacokinetic issues observed with prior CD39
antibodies.”
Presentation highlights:
Poster presentation titled, “Identification of conditionally
active antibodies that selectively block CD39 activity in the
acidic tumor microenvironment”
- CD39 is commonly upregulated in the tumor microenvironment,
which is characterized by high levels of extracellular ATP (eATP)
and low pH. Upregulation and activation of CD39 results in
significant reductions of eATP and a rise in immunosuppressive
adenosine.
- SNS-103 is aimed at developing an antibody that binds to CD39
only under low pH conditions such as those found in the tumor
microenvironment and achieves a high target occupancy selectively
in the tumor, while maintaining extracellular ATP and inhibiting
adenosine generation to enhance anti-tumor immunity.
- From a panel of 83 antibodies identified and characterized for
CD39 inhibition at neutral and acidic pH, Sensei has selected 8
antibodies for further optimization.
- Sensei intends to select a lead product candidate for SNS-103
in 2023.
The full poster is available for viewing on Sensei’s corporate
website.
About Sensei BiotherapeuticsSensei
Biotherapeutics (Nasdaq: SNSE) is an immuno-oncology company
focused on the discovery and development of next-generation
therapeutics for cancer patients. Through its TMAb™ (Tumor
Microenvironment Activated biologics) platform, Sensei develops
conditionally active therapeutics designed to disable
immunosuppressive signals or activate immunostimulatory signals
selectively in the tumor microenvironment to unleash T cells
against tumors. Sensei’s lead investigational candidate is SNS-101,
a conditionally active antibody designed to block the V-domain Ig
suppressor of T cell activation (VISTA) checkpoint selectively
within the low pH tumor microenvironment, where VISTA acts as a
suppressor of T cells by binding the receptor PSGL-1. The company
is also developing SNS-102, a conditional binding monoclonal
antibody targeting V-Set and Immunoglobulin Domain Containing 4
(VSIG-4), as well as SNS-103, also a conditionally active
monoclonal antibody targeting ecto-nucleoside triphosphate
diphosphohydrolase-1 (ENTPDase1), also known as CD39. For
more information, please visit www.senseibio.com, and follow
the company on Twitter @SenseiBio and LinkedIn.
Cautionary Note Regarding Forward-Looking
StatementsAny statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements may be
identified by words and phrases such as “aims”, believe”, “designed
to”, “expect”, “may”, “plan”, “potential”, “will”, and similar
expressions, and are based on Sensei’s current beliefs and
expectations. These forward-looking statements include expectations
regarding the development of Sensei’s product candidates and
platforms, including SNS-103; the potential safety profile of
Sensei’s product candidates, including SNS-103; the potential
benefits of Sensei’s product candidates, including SNS-103,
including the potential to overcome pharmacokinetic and safety
issues associated with targeting the CD39 immune checkpoint,
including target-mediated drug disposition and cytokine release
syndrome. These statements involve risks and uncertainties that
could cause actual results to differ materially from those
reflected in such statements. Risks and uncertainties that may
cause actual results to differ materially include uncertainties
inherent in the development of therapeutic product candidates, such
as the risk that any one or more of Sensei’s product candidates
will not be successfully developed or commercialized; the risk that
Sensei will not identify an antibody that is suitable for selection
as the lead product candidate for SNS-103; the risk of delay or
cessation of any planned clinical trials of Sensei’s product
candidates; the risk that prior results, such as signals of safety,
activity or durability of effect, observed from preclinical
studies, including the preclinical studies described in this press
release, will not be replicated or will not continue in ongoing or
future studies or clinical trials involving Sensei’s product
candidates; the risk that Sensei’s product candidates or procedures
in connection with the administration thereof will not have the
safety or efficacy profile that we anticipate; risks associated
with Sensei’s dependence on third-party suppliers and
manufacturers, including sole source suppliers, over which we may
not always have full control; risks regarding the accuracy of our
estimates of expenses, capital requirements and needs for
additional financing; and other risks and uncertainties that are
described in Sensei’s Annual Report on Form 10-K filed with the
U.S. Securities and Exchange Commission (SEC) on March 29, 2023 and
Sensei’s other Periodic Reports filed with the SEC. Any
forward-looking statements speak only as of the date of this press
release and are based on information available to Sensei as of the
date of this release, and Sensei assumes no obligation to, and does
not intend to, update any forward-looking statements, whether as a
result of new information, future events or otherwise.
Investor Contact:Michael
BiegaSenior Director, Investor RelationsSensei
Biotherapeuticsmbiega@senseibio.com
Media Contact:Chris RaileyTen
Bridge Communicationschris@tenbridgecommunications.com
Grafico Azioni Sensei Biotherapeutics (NASDAQ:SNSE)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Sensei Biotherapeutics (NASDAQ:SNSE)
Storico
Da Lug 2023 a Lug 2024